Grifols (NASDAQ:GRFS) Issues Earnings Results, Misses Estimates By $0.14 EPS

Grifols (NASDAQ:GRFS) issued its earnings results on Thursday. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.14), FiscalAI reports.

Here are the key takeaways from Grifols’ conference call:

• Grifols generated EUR 468 million free cash flow in FY‑2025 (pre‑M&A/pre‑dividends), up >€200m year‑over‑year, and guided 2026 free cash flow to EUR 500–575 million.
• Management is deliberately prioritizing profitability and cash generation over top‑line growth in 2026, targeting an adjusted EBITDA margin of at least 25% and adjusted EBITDA growth of 5–9% on a constant‑currency basis.
• The immunoglobulin franchise outperformed, with IG growth of 14.7% (IVIG +12%, SCIG +60%) driven by GAMUNEX‑C and XEMBIFY and deliberate share gains in the U.S.
• Strategic self‑sufficiency projects are a core value driver — EMA approval for Egyptian‑sourced plasma and the Canada partnership (raising IG self‑sufficiency to ~30% in 2025) are positioned to lower costs and support long‑term margin expansion.
• Albumin weakness in China, together with the IRA impact and certain accounting reclassifications, weighed on gross margins and EBITDA comparability, creating near‑term margin headwinds despite resilient free cash flow.

Grifols Stock Down 3.1%

NASDAQ GRFS traded down $0.29 during trading hours on Thursday, hitting $8.96. 2,324,217 shares of the company were exchanged, compared to its average volume of 444,352. Grifols has a 52 week low of $6.19 and a 52 week high of $11.14. The company has a current ratio of 2.48, a quick ratio of 0.93 and a debt-to-equity ratio of 1.20. The stock has a 50-day moving average price of $9.22 and a 200 day moving average price of $9.37.

Wall Street Analyst Weigh In

GRFS has been the topic of a number of recent research reports. Wall Street Zen raised Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. Zacks Research raised Grifols from a “strong sell” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Four investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of Grifols

Several hedge funds and other institutional investors have recently bought and sold shares of GRFS. Bank of Montreal Can boosted its stake in Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after buying an additional 2,922,540 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock worth $27,894,000 after acquiring an additional 2,221,633 shares during the last quarter. Barclays PLC boosted its stake in shares of Grifols by 132.6% during the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after purchasing an additional 1,387,783 shares during the period. Bank of America Corp DE grew its holdings in Grifols by 52.1% during the 2nd quarter. Bank of America Corp DE now owns 3,017,675 shares of the biotechnology company’s stock valued at $27,280,000 after purchasing an additional 1,034,229 shares during the last quarter. Finally, Permian Investment Partners LP grew its holdings in Grifols by 4.2% during the 4th quarter. Permian Investment Partners LP now owns 18,190,262 shares of the biotechnology company’s stock valued at $170,079,000 after purchasing an additional 737,941 shares during the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.